{"id":"NCT02624869","sponsor":"Amgen","briefTitle":"Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)","officialTitle":"Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-10","primaryCompletion":"2021-06-01","completion":"2021-06-01","firstPosted":"2015-12-09","resultsPosted":"2022-01-14","lastUpdate":"2024-05-29"},"enrollment":163,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Familial Hypercholesterolemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["Repatha®","AMG 145"]}],"arms":[{"label":"Evolocumab","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.","effectByArm":[{"arm":"HeFH (Placebo in Parent Study): Evolocumab 420 mg QM","deltaMin":36,"sd":null},{"arm":"HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM","deltaMin":69,"sd":null},{"arm":"HoFH: Evolocumab 420 mg QM","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":46,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Greece","Hungary","Italy","Malaysia","Netherlands","Norway","Poland","Portugal","Russia","Slovenia","South Africa","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["36075246","38545781","37855448"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":49},"commonTop":["Nasopharyngitis","Headache","Influenza like illness","Gastroenteritis","Upper respiratory tract infection"]}}